Treatment of Syphilis in Pregnancy and Congenital Syphilis: Current Evidence, Challenges, and Future Directions
Antibiotics · 18.03.2026 · 15 (3) · 305
DOI: 10.3390/antibiotics15030305 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 18.03.2026. Verfasst von Serena Salomè und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neonatology, Department of Translational Medical Sciences, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Syphilis remains a global public health concern, with maternal infection posing a substantial risk for congenital syphilis, a preventable condition associated with severe morbidity and mortality. Penicillin, particularly benzathine penicillin G, remains the cornerstone of treatment and the only therapy with proven efficacy in preventing vertical transmission during pregnancy. However, recurrent global shortages, limited manufacturing capacity, mislabeling of penicillin allergy, and the absence of validated alternative regimens for pregnant women and neonates threaten progress toward elimination goals. This review summarizes current evidence on the treatment of syphilis in pregnancy and congenital syphilis, highlighting the established maternal and neonatal regimens, diagnostic and therapeutic challenges, and clinical consequences of delayed or inadequate treatment. We examine the scope and drivers of benzathine penicillin G shortages, the overestimation of penicillin allergy and its impact on care, and the role of neonatal management when maternal therapy is suboptimal. Emerging data on alternative antimicrobial agents, including cephalosporins, tetracyclines, lipoglycopeptides, and novel compounds are discussed considering recent advances in Treponema pallidum culture and susceptibility testing. While several non-penicillin agents show promise for non-pregnant populations, robust evidence supporting their use during pregnancy and for the prevention of congenital syphilis is lacking. Addressing these gaps through coordinated supply chain strategies, guideline harmonization, and targeted clinical research is essential to ensure resilient and equitable syphilis control and advance global efforts toward the elimination of congenital syphilis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neonatology, Department of Translational Medical Sciences, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy.
- Neonatal Intensive Care Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.
ORCID-Profile: Serena Salomè
Zitieren
APA
Salomè, S., & Tzialla, C. (2026). Treatment of Syphilis in Pregnancy and Congenital Syphilis: Current Evidence, Challenges, and Future Directions. Antibiotics, 15(3), 305. https://doi.org/10.3390/antibiotics15030305
Vancouver
Salomè S, Tzialla C. Treatment of Syphilis in Pregnancy and Congenital Syphilis: Current Evidence, Challenges, and Future Directions. Antibiotics. 2026;15(3):305. doi:10.3390/antibiotics15030305
BibTeX
@article{Salom2026,
author = {Salomè, Serena and Tzialla, Chryssoula},
title = {Treatment of Syphilis in Pregnancy and Congenital Syphilis: Current Evidence, Challenges, and Future Directions},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {3},
pages = {305},
doi = {10.3390/antibiotics15030305}
}
EUVIMED